Peter Hardwick is U.S. President and CEO of Apotex Corporation.
Peter is responsible for Apotex's global commercial strategy for all generic market segments. He joined Apotex as Director of Marketing Canada and took on expanded roles within the Canadian market.
Peter has 27 years of Pharma experience in sales and marketing, international management, and held P&L responsibility of core countries within a Global Pharmaceutical company. He has both brand and generic experience, including five years abroad based in Basel Switzerland working for Mepha Inc., which specialized in branded generics.
As AAM Board Initiative Sponsor, Peter advocates for policies in the U.S. and in trade agreements that appropriately balance innovation with access to more affordable generic and biosimilar medicines.
Peter has a Bachelor of Science in Biology from St. Mary's University and is a graduate of the Ashridge Executive Management Program in London, UK.